We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

66 hedge funds and large institutions have $17.9M invested in Protalix BioTherapeutics in 2023 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

457% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 7

237% more call options, than puts

Call options by funds: $2.82M | Put options by funds: $838K

196% more capital invested

Capital invested by funds: $6.04M → $17.9M (+$11.9M)

150% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 6

94% more funds holding

Funds holding: 34 → 66 (+32)

8.17% more ownership

Funds ownership: 5.12% → 13.29% (+8.2%)

Holders
66
Holders Change
+32
Holders Change %
+94.12%
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
39
Increased
15
Reduced
6
Closed
7
Calls
$2.82M
Puts
$838K
Net Calls
+$1.98M
Net Calls Change
-$1.18M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.02M
2
State Street
State Street
Massachusetts
+$1.74M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.32M
4
Marshall Wace
Marshall Wace
United Kingdom
+$981K
5
Northern Trust
Northern Trust
Illinois
+$865K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$1.31M
2
Citadel Advisors
Citadel Advisors
Florida
-$504K
3
MIH
Meitav Investment House
Israel
-$494K
4
Two Sigma Investments
Two Sigma Investments
New York
-$331K
5
Millennium Management
Millennium Management
New York
-$156K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
51
T. Rowe Price Associates
Maryland
$23K +$27.3K +11,447 New
KAS
52
Kestra Advisory Services
Texas
$23K +$27.4K +11,500 New
HIM
53
Harbour Investment Management
Washington
$20.2K +$24.1K +10,100 New
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$13K +$15.5K +6,499 New
AB
55
Amalgamated Bank
New York
$11K +$13K +5,463 New
TWC
56
TD Waterhouse Canada
Ontario, Canada
$10.9K – – –
Legal & General Group
57
Legal & General Group
United Kingdom
$10.7K +$12.8K +5,359 New
AIP
58
Ameritas Investment Partners
Nebraska
$9.28K +$11.1K +4,638 New
TC
59
Truvestments Capital
Florida
$7.76K – – –
MLICM
60
Metropolitan Life Insurance Company (MetLife)
New York
$6.71K +$7.99K +3,354 New
TRCT
61
Tower Research Capital (TRC)
New York
$5.18K +$2.36K +990 +62%
Osaic Holdings
62
Osaic Holdings
Arizona
$1.2K -$2 -1 -0.2%
WP
63
WealthPLAN Partners
Nebraska
$1.15K +$1.37K +575 New
NA
64
NewEdge Advisors
Louisiana
$1.07K +$1.28K +536 New
FDCDDQ
65
Federation des caisses Desjardins du Quebec
Quebec, Canada
$500 – – –
Fidelity Investments
66
Fidelity Investments
Massachusetts
$210 +$250 +105 New
MIH
67
Meitav Investment House
Israel
– -$494K -244,332 Closed
Citadel Advisors
68
Citadel Advisors
Florida
– -$504K -211,548 Closed
CIBC World Market
69
CIBC World Market
Ontario, Canada
– -$52K -25,000 Closed
Two Sigma Advisers
70
Two Sigma Advisers
New York
– -$41.8K -19,900 Closed
HF
71
HRT Financial
New York
– -$21K -10,309 Closed
Federated Hermes
72
Federated Hermes
Pennsylvania
– -$12.1K -5,761 Closed
PVH
73
Psagot Value Holdings
Israel
– -$7K -3,744 Closed
1 2
3

PLX Hedge Fund Activity: Q2 2023 in Review

66 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2023, worth a combined $17.9M — up 196% from $6.04M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new PLX positions and 7 closed out — a net gain of 32 holders — while 15 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, adding an estimated $6.02M. The largest seller was Renaissance Technologies, cutting an estimated $1.31M.

  • 66 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2023, up from 34 in Q1 2023.
  • Funds reported $17.9M of Protalix BioTherapeutics stock for Q2 2023, up 196% quarter-over-quarter.
  • 39 funds opened new Protalix BioTherapeutics positions in Q2 2023 and 7 closed out, a net change of +32 holders.
  • The largest Protalix BioTherapeutics buyer in Q2 2023 was BlackRock, an estimated $6.02M added.
  • The largest Protalix BioTherapeutics seller in Q2 2023 was Renaissance Technologies, an estimated $1.31M sold.

Based on aggregated 13F filings for Q2 2023.